On May 23, 2024 Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, reported that it will showcase data from across its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 31-June 4 (Press release, Servier, MAY 23, 2024, View Source [SID1234643643]). New data including two abstracts highlight Servier’s continued leadership in IDH-inhibition.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Among the data to be presented are preliminary findings from real-world evidence that show trends on treatment patterns in newly diagnosed acute myeloid leukemia (AML) patients. Servier will also share initial results from a Phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma (CCA).
"Servier is doubling down its conviction to address the unmet needs of patients battling cancer, and our dedication shines through as we prepare to attend and present at ASCO (Free ASCO Whitepaper) this year," said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "With over half of our global research & development budget allocated to oncology, our team is committed to advancing scientific studies and being open to innovation both through internal and external means. We’re focused on advancing our reputation of being a key innovator in cancer treatment and are actively seeking partnerships that can expedite access to life-changing therapies for patients."
For more information on Servier’s abstracts for ASCO (Free ASCO Whitepaper), please visit ASCO (Free ASCO Whitepaper)’s website.